Table 3 Estimates of the impact of pre-transplantation obesity and diabetes on grade II–IV acute graft-versus-host disease and other transplant outcomes from multivariable cause-specific Cox proportional hazard regression models.

From: The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Outcome

Reference: Control group

Adjusteda HR [95% CI]

P

Grade II–IV acute GvHD

Obesity

1.00 [0.94–1.06]

0.89

Diabetes

0.95 [0.85–1.07]

0.43

Obesity + Diabetes

0.96 [0.82–1.13]

0.63

Chronic GvHD (limited + extensive)

Obesity

1.04 [0.98–1.10]

0.17

Diabetes

1.02 [0.92–1.14]

0.68

Obesity + Diabetes

1.07 [0.93–1.25]

0.34

Extensive chronic GvHD

Obesity

1.00 [0.92–1.08]

0.92

Diabetes

1.07 [0.92–1.25]

0.37

Obesity + Diabetes

1.18 [0.97–1.44]

0.10

Overall survival

Obesity

1.02 [0.97–1.08]

0.38

Diabetes

1.29 [1.18–1.40]

<0.0001

Obesity + Diabetes

1.23 [1.09–1.39]

0.001

Relapse

Obesity

1.02 [0.96–1.08]

0.53

Diabetes

1.08 [0.96–1.20]

0.20

Obesity + Diabetes

0.96 [0.81–1.13]

0.61

Non-relapse mortality

Obesity

1.08 [1.00–1.17]

0.047

Diabetes

1.40 [1.24–1.57]

<0.0001

Obesity + Diabetes

1.38 [1.16–1.64]

0.0003

Overall survival after grade II–IV acute GvHD

Obesity

1.02 [0.93–1.13]

0.65

Diabetes

1.46 [1.25–1.70]

<0.0001

Obesity + Diabetes

1.18 [0.95–1.47]

0.14

  1. For the landmark analysis of OS after acute GvHD grade II–IV, grade of acute GvHD and time between transplantation and acute GvHD (logarithmic transformation of the continuous time) were also added to the covariate set.
  2. aThe following covariates were included: previous autologous transplantation (yes vs. no), year of transplantation (continuous), cell source (bone marrow vs. peripheral blood), type of donor (identical sibling vs. matched unrelated donor vs. mismatched unrelated donor vs. haploidentical donor), Disease Risk Index (high-very high vs. low-intermediate), patient age (continuous), patient and donor sex (male vs. female), patient and donor CMV (negative vs. positive), Karnofsky score (≥90 vs. < 90), intensity of conditioning (RIC vs. MAC), TBI (yes vs. no), and use of ATG/Campath (yes vs. no).
  3. CI confidence interval, GvHD graft-versus-host disease, HR hazard ratio.
Back to article page